Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial

• Published in: Stroke (1970) Vol. 53; no. 2; pp. 465 - 472
• Main Authors: Dai, Liye, Xu, Jie, Yan, Hongyi, Chen, Zimo, Pan, Yuesong, Meng, Xia, Li, Hao, Wang, Yongjun
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01.02.2022
• Subjects: Age Factors; Aged; Aspirin - therapeutic use; Body Mass Index; Cerebrovascular Disorders - drug therapy; Cerebrovascular Disorders - genetics; Clopidogrel - therapeutic use; Cytochrome P-450 CYP2C19 - genetics; Diabetes Mellitus; Drug Therapy, Combination; Female; Genotype; Humans; Ischemic Attack, Transient - drug therapy; Male; Middle Aged; Platelet Aggregation Inhibitors - therapeutic use; Recurrence; Renal Insufficiency, Chronic - complications; Stroke - drug therapy; Treatment Outcome; clopidogrel; risk factors; stroke; genotype

The age, body mass index, chronic kidney disease, diabetes, and genotyping (ABCD-GENE) score is a validated risk score integrating CYP2C19 genotypes with clinical risk factors influencing clopidogrel response that would allow the more precise identification of subjects at risk for high platelet reac...